Stay updated on Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check10 days agoChange DetectedThe page has updated the revision number from v2.16.1 to v2.16.2, and the previous publication of the KEYNOTE-087 study has been removed, which included an erratum notice.SummaryDifference0.3%
- Check17 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check24 days agoNo Change Detected
- Check46 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check60 days agoChange DetectedThe page has been updated to include new information about Hodgkin Lymphoma and a new registry identifier, while significant details about the clinical trial and its criteria have been removed.SummaryDifference11%
- Check67 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.